The relationship between renal disease and cardiovascular disease (CVD) is currently known as cardiorenal syndrome. Indoxyl sulfate (IS) is one of the uremic toxins that accelerates the progression of cardiorenal syndrome. This report presents a new method for measuring IS in a simpler way. Methods: We evaluated the analytical performance of an IS Assay Kit "NIPRO" loaded on LABOSPECT 008. The evaluated analytical performances included accuracy, precision, dilution linearity, limit of detection (LOD), limit of quantitation (LOQ), recovery test, interference test and comparison against assays performed by high-performance liquid chromatography (HPLC). Results: Total precision showed a <5.3% coefficient of variation at IS concentrations of 3.57-277.73 μmol/L, and satisfactory results were observed in the dilution linearity, LOD, LOQ, recovery and interference tests. The IS Assay Kit "NIPRO" showed a high correlation with the HPLC conventional method (r = 0.993).
Introduction
Indoxyl sulfate (IS) is a uremic toxin generated by the metabolism of dietary protein-bound tryptophan. Through the function of the gut microbiota, tryptophan is cleaved to indole and becomes absorbed into the blood from the intestine; indole is then oxidized and sulfated to IS in the liver. Although IS is normally excreted into urine by an organic anion transport system [1] , in conditions of renal dysfunction, the clearance of IS is reduced, which causes its accumulation in the blood. Recently, IS has been claimed to be associated with cardiorenal syndrome [2, 3] . The most common mortality risk of renal disease patients is cardiovascular disease (CVD), and IS is one of the uremic toxins associated with this interrelationship [3, 4] . Regarding the nephrotoxicity of IS, Niwa demonstrated a protein-metabolite theory [5, 6] , which suggests its significant role in the progression of chronic kidney disease. Regarding vascular toxicity, IS contributes to the enhancement of aortic calcification, arterial stiffness [7] , inhibition of endothelial cell proliferation [8] , and the induction of endothelial senescence [9] and oxidative stress [10] [11] [12] . Recent reports suggest that the higher levels of serum IS are associated with a risk of higher mortality due to CVD [7] and that IS, especially the free fraction, may be a prognostic factor for patients with acute coronary syndrome [13] . For these reasons, it is significant to determine the circulating levels of IS.
In most facilities, IS is examined by high-performance liquid chromatography (HPLC). Our laboratory is one of the facilities that uses Niwa's internal-surface reversedphase HPLC (ISRP-HPLC) method [14] , which enables the user to determine the circulating IS concentration without deproteinization. However, this method requires skill, an expenditure in preparing the equipment, and each facility also uses its own standard solutions.
NIPRO (Osaka, Japan) has recently developed a research reagent, IS Assay Kit "NIPRO", which enables the examination of IS by an enzymatic assay despite the presence of albumin. This reagent is loadable on an automated analyzer, which solves the problem of required skills, the necessity of preparing the new apparatus, and standards can be shared in one exclusive calibrator. This assay is commercially available only for research use, and this is the first paper to perform analytical evaluations using human samples.
As our laboratory routinely measures the IS values of patients for research, which is approximately 500-1000 samples per year, we examined the analytical performance of the IS Assay Kit "NIPRO" and compared the IS values obtained by the kit with those obtained by the HPLC conventional method. The analyzed performances were as follows: accuracy, precision, dilution linearity, limit of detection (LOD), limit of quantitation (LOQ), recovery test, interference test and method comparison.
Materials and methods

Assay principle
Indoxyl Sulfate (IS) Assay Kit "NIPRO": All of the IS concentrations were analyzed using the IS Assay Kit "NIPRO" loaded on the LABOS-PECT 008 automated analyzer (Hitachi High-Technologies, Tokyo, Japan). By the function of the sulfatase contained in the reagent, the serum/plasma IS is converted into indoxyl, which then reacts with water-soluble tetrazolium salts (WST-8) to generate formazan ( Figure 1 ). The dye formation is monitored by measuring the absorbance at 450 nm and is directly proportional to the IS concentration. A total of 8 μL of sample is required in each assay. Heparinized plasma and serum samples for the correlation tests were stored at −80 °C until HPLC analysis was conducted.
HPLC: Samples for the correlation test were analyzed by reversedphase HPLC using GULLIBER (JASCO Corporation, Tokyo, Japan). The column used was Capcell Pak MF Ph-1 SG80S5 4.6 mm I.D. × 150 mm (SHISEIDO Co., Ltd., Tokyo, Japan). For the mobile phase, dilute acetic acid and 0.1 M KH 2 PO 4 /tetrahydrofuran (95/5, V/V) was adjusted to pH 6.5 and was delivered at a flow rate of 1.0 mL/min at 37 °C. The eluate was monitored by the detection of absorbance at 295 nm. The samples are diluted 1/10 with ultrapure water before the run. A total of 10 μL of sample is required in each assay.
Specimens
In accordance with the local ethics regulation of the Department of Clinical Laboratory, Toho University Omori Medical Center (Tokyo, Japan), blood samples were obtained from remnant samples of physician-ordered routine testing. The Ethics Committee specifically approved the research of this study (protocol number M1709417303). Lithium heparinized plasma and serum samples were collected; the plasma samples were centrifuged at 1561 × g for 5 min, and the serum samples were centrifuged at 1561 × g for 10 min. Each analytical performance was conducted using lithium heparinized plasma, and serum samples were only used in the assay for the comparison between plasma and serum. The supernatant was aliquoted and stored at −80 °C after the IS testing performed by LABOSPECT 008. The IS calibrators were provided by NIPRO (Japan).
Analytical performance studies
Accuracy: The accuracy test was performed using the provided NIPRO calibrator according to the Japanese Society of Clinical Chemistry (JSCC) guideline [15] . After the calibration, the calibrator was measured 10 times to calculate the average, standard deviation (SD) and 95th percentile confidence interval.
Precision study: The assay precision was determined across the dynamic range using pooled lithium heparinized plasma samples according to the JSCC guideline [15] . Intra-day precision was determined by measuring three levels of IS 20 times to calculate the percent coefficient of variation (CV%). For inter-day precision, three levels of IS were aliquoted and stored at −80 °C until analysis. Two IS tests were prepared for the difference in the frequency of calibration. Test type 1 was calibrated only on the first day of the assay, whereas test type 2 was calibrated every day of the assay. The samples were assayed twice a day for 20 days within a month to calculate the CV%. Pooled samples were prepared separately for intra-and inter-day precision due to the lack of patient samples.
Dilution linearity:
The dilution linearity was evaluated at all 10 sites using lithium heparinized plasma samples with one high concentration sample and one medium concentration sample. Each plasma sample was serially diluted from 1:9 to 9:1 using the exclusive diluent supplied by NIPRO. Each dilution was performed in duplicate according to the JSCC guideline [15] . The target concentration for each linearity sample was calculated based on the resulting equation of linearity.
Limit of detection: Lithium heparinized plasma samples with an IS concentration of 5 μmol/L were serially diluted (1:9-9:1) by the diluent, and each sample was measured 20 times. The LOD was estimated as 2.6 SDs above the blank value. Limit of quantitation: Lithium heparinized plasma with mean IS concentrations (0.16, 0.51, 0.75, 1.44 and 1.79 μmol/L) were measured twice a day for a total of 5 days and calculated based on the JSCC guideline [16] .
Recovery test: Pooled heparinized plasma samples were aliquoted and supplemented with three different standards containing 4.93, 49.3 and 98.6 μmol/L of IS. IS non-containing diluent and the three IS containing aliquots were assayed in triplicate.
Interference test: An interference test was examined using Check A Plus (Sysmex, Kobe, Japan), which contains a conjugated form of bilirubin (bilirubin C), a free form of bilirubin (bilirubin F), hemolytic hemoglobin and chyle. By following the instructions of the attached document, bilirubin C (207 mg/dL), bilirubin F (191 mg/dL), hemolytic hemoglobin (4900 mg/dL) and chyle (16500 FTU) were added to the pooled samples, serially diluted in six points, and each sample was assayed in triplicate. Reduced glutathione (200 mg/dL) and ascorbic acid (500 mg/dL) were also added to the pooled samples, serially diluted and assayed in triplicate.
Method comparison:
According to the Japanese Committee for Clinical Laboratory Standards (JCCLS) guideline [17] , 200 randomly selected lithium heparinized patient samples were analyzed using the IS Assay Kit "NIPRO". After the analysis, the samples were stored at −80 °C until the HPLC analysis. Parallel testing of the 200 samples was performed by HPLC as the comparative procedure. In addition, the correlation equation, correlation coefficient and covariance were determined, and the Bland-Altman analysis was also examined [18] .
Comparison between plasma and serum samples:
Based on the JCCLS guideline [17] , lithium heparinized plasma and serum samples (n = 30), which were both taken from the same patient at the same time, were analyzed using the NIPRO assay to calculate the correlation equation, correlation coefficient and covariance between plasma and serum samples.
Stability test: Three levels of heparinized plasma samples were pooled according to the IS concentrations (3.47, 17.95 and 234.52 μmol/L) and were aliquoted and stored at 4 °C and −80 °C until analysis. The samples were assayed on day 0, 1, 2, 3, 8, 14, 21 and 31 at each temperature condition and assayed in triplicate. The samples were also stored at room temperature and assayed on day 0, 1, 2 and 3. A calibration was conducted every day before the assay.
Results
Accuracy
The accuracy test was performed using the NIPRO calibrator. The indicated value of 42.0 μmol/L was within the 95% confidence interval (41.58-42.13).
Precision study
The total precision was observed at a satisfactory CV of less than 6%. For intra-day precision, the total CVs ranged from 0.52 to 5.27%. For inter-day precision, the results of the test type 1 showed satisfactory CVs ranging from 0.43 to 3.15%. For the results of the test type 2, the total CVs ranged from 0.71 to 3.24% ( Table 1) . The difference in the frequencies of calibration were not significant.
Dilution linearity
The dilution linearity of IS was satisfactory for both the medium and high concentrations of IS. For the medium concentrations (average concentration, 54.21 μmol/L), the maximum alteration from the target recovery was 10.4%, and the slope was 1.05. For the high concentrations (average concentration, 317.65 μmol/L), the maximum alteration from the target recovery was 3.9%, and the slope was 1.01.
Limit of detection
Lithium heparinized plasma samples with an IS concentration of 5 μmol/L were serially diluted (1:9-9:1) by the diluent, and each sample was measured 20 times. The LOD was estimated as 2.6 SDs above the blank value. The mean LOD was 0.78 μmol/L.
Limit of quantitation
Lithium heparinized plasma with various mean IS concentrations (0.16, 0.51, 0.75, 1.44 and 1.79 μmol/L) were measured, and the value at CV = 10% was 1.51 μmol/L. 
Recovery test
Pooled heparinized plasma samples were aliquoted and supplemented with three different standards containing 4.93, 49.3 and 98.6 μmol/L of IS. IS non-containing diluent and the three IS containing aliquots were assayed in triplicate. The % recovery ranged from 86 to 109% (Table 2) .
Interference test
The alteration of IS values was within 8% of the expected samples following supplementation with high concentrations of interfering substances (19.1 mg/dL bilirubin F, 490 mg/dL hemoglobin, 1650 formazin turbidity of chyle, 20 mg/dL reduced glutathione and 50 mg/dL ascorbic acid). Samples to which bilirubin C was added decreased the IS value in a dose-dependent manner, and the maximum alteration was 14% ( Table 3) .
Method comparison
The observed correlation equation, correlation coefficient and covariance between the IS Assay Kit "NIPRO" and HPLC were y = 1.44x - 0.94, r = 0.993 and Syx = 7.83, respectively. The Bland-Altman analysis showed a combined mean bias of 16.08 μmol/L (±2 SD, −27.83 to 59.99) ( Figure 2 ). The IS value measured using the IS Assay Kit "NIPRO" was biased higher than that of HPLC. To determine the reason for the positive bias, we measured the NIPRO calibrator by HPLC and compared it with 1 mg/dL of IS, which was the standard used in HPLC. The calculated value was approximately 15% higher in the NIPRO calibrator (data not shown). Therefore, we predict that by using the same standards, we would obtain a consistent bias. Out of the 200 patient samples, 66 randomly selected samples were measured again using the same NIPRO calibrator for both apparatuses. The observed correlation equation, correlation coefficient and covariance were y = 1.17x - 0.34, r = 0.993 and Syx = 10.1, respectively, and the Bland-Altman plot showed a combined mean bias of 10.86 μmol/L (±2 SD, −20.26 to 41.99) (Figure 3 ).
Comparison between plasma and serum samples
The observed correlation coefficient between the plasma and serum samples was r = 0.998, and the equation for the line-of-best-fit was y = 0.99x - 1.32 (Figure 4) . Similar results were observed for plasma and serum samples.
Stability test
Samples stored at −80 °C showed a satisfactory stability in all three levels. The alteration rate observed on day 31 was 1.3%, 2.3% and 0.9% for IS concentrations that were low, medium and high, respectively. For the samples stored at 4 °C, the IS values showed an increase day by day. On day 31, the IS values were 12.7%, 9.3% and 6.2% higher, respectively, than on the first day of measurement. Although the samples stored at room temperature were only measured until day 3, the increase in the alteration rate was similar to that observed in the samples stored at 4 °C. The alteration rates observed on day 3 were 12.1%, 3.9% and 1.3%, respectively ( Figure 5 ).
Discussion
Currently, the most common IS assay is performed by HPLC. NIPRO has developed a research reagent, which allows the quantitation of IS in serum/plasma using an enzymatic assay. Here, we provide the analytical performance of this assay. The accuracy, precision, dilution linearity, LOD, LOQ and the recovery test showed satisfactory results. The interference test suggests that icterus samples may be negatively biased as the quantitation wavelength of IS at 450 nm overlaps the absorbance curve of bilirubin C. During the reaction for measuring IS, bilirubin is oxidized, which causes it to lose its color and leads to a decrease in the absorbance.
The comparison of the IS values measured using the IS Assay Kit "NIPRO" and HPLC showed a satisfactory correlation. However, the IS values measured by "NIPRO" were biased 40% higher than that of HPLC. As the two methods have different principles and there is no common standard for IS yet, the two methods use their own standards: the calibrator provided by NIPRO for the IS Assay Kit "NIPRO" and 1 mg/dL of IS for HPLC. Therefore, we hypothesized that, by using the same standards, the IS values measured by both methods would show a consistent bias.
Using the same calibrator, we measured 66 samples that were selected from the 200 samples previously measured in the correlation test. The correlation equation was y = 1.17x - 0.34, which showed a lower bias. We found that the difference in the standards was one of the reasons why "NIPRO" showed a positive bias. NIPRO should better reconsider the indicated value of the calibrator and the 17% of the bias will remain a task. We also recommend making a common standardized material as the calibrator for the entire IS assay.
According to Shafi et al., heparin could affect the ratio of free to bound IS [19] . As the NIPRO assay measures the total IS, heparin does not affect the ratio. However, to determine the effect of heparin in the reaction of the assay, we compared the IS values between the heparinized plasma and serum samples collected from the same patients taken at the same time. The result showed an excellent agreement, and as similar results were observed in the assay performed by HPLC (no data), we suggest that there is no effect in the IS value even in the presence of heparin.
The stability test suggests that samples should be measured immediately after centrifugation, and if not, the samples should be stored at −80 °C.
Recently, a free fraction of IS was presumed to be associated with the risk of death. However, the IS Assay Kit "NIPRO" measures the total (free and protein-bound) IS in the blood and ultrafiltrated samples are required to examine the free fraction. It remains a challenge to determine a way to examine free IS without ultrafiltration.
Conclusions
The IS Assay Kit "NIPRO" demonstrated satisfactory results in each examination. By sharing the same standards, the IS values showed a relatively consistent bias with the values measured by HPLC.
Although it is still difficult to examine the free fraction of IS without ultrafiltration, using an automated analyzer will permit any researcher to measure this value, as it does not require complicated manipulations and can be measured with other test items at the same time. This is the first paper to announce an IS assay using an automated analyzer, and we successfully achieved an evaluation of the basic analytical performances for diagnostic use. This assay may shortly become a common method for measuring circulating total IS.
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